JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
What's the purpose of the trial?
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C34.129601%2C-117.971001%7C33.66946%2C-117.82311%7C40.764198%2C-73.956703%7C40.790001%2C-73.953697%7C39.746535%2C-104.966175%7C39.9478%2C-75.192497%7C29.707199%2C-95.396698%7C37.768342%2C-122.394191%7C35.2062%2C-80.838203)
Participating Centers
There are 9 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- JNJ-79635322 is a trispecific antibody that targets BCMA and GPRC5D on cancer cells, and CD3 on our own immune cells.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.